CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
CHF 5074 1x +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01303744
NCT01303744Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment

CERESPIR·interventional·Posted Feb 25, 2011·Updated Jan 11, 2016

In Brief

A Phase 2 clinical trial evaluating CHF 5074 1x, CHF 5074 2x, and 2 other interventions for Alzheimer's Disease. Completed, enrolled 96 participants across 9 sites in 2 countries.

Detailed Summary

To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesItaly, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2011
Enrollment StartMar 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.4 years ago

Interventions

CHF 5074 1xdrug

oral tablet, 1x, once a day in the morning for 12 weeks

CHF 5074 2xdrug

oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks

CHF 5074 3xdrug

oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks

Placebodrug

oral tablet, once a day in the morning for 12 weeks